Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View

Bando H^1,2*

¹Medical Research / Tokushima University, Tokushima, Japan

²Japan low carbohydrate diet promotion association (JLCDPA), Kyoto, Japan

Corresponding Author: Hiroshi Bando, MD, PhD, FACP

Address: Tokushima University/ Medical Research, Nakashowa 1-61, Tokushima 770-0943 Japan; TEL: +81-90-3187-2485; E-mail: pianomed@bronze.ocn.ne.jp

Received date: 22 January 2020; Accepted date: 25 January 2020; Published date: 30 January 2020

Citation: Bando H. Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View. Diab Res. 2020 Jan 30;2(S1):9-13.

Copyright © 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors; Canagliflozin Cardio-Vascular Assessment Study (CANVAS); Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE); Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58; The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) Study

Abstract

Diabetes has been a major medical and health problem worldwide. Adequate glycemic control has shown a clinically beneficial effect for long-term prognosis, with recent anti-diabetic agents. There are some mega studies concerning Sodium-glucose cotransporter 2 (SGLT2) inhibitors. They are i) Canagliflozin cardioVascular Assessment Study (CANVAS), ii) Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), iii) Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58, iv) Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study. Current topics of SGLT2 inhibitors for cardiovascular and renal points of view were described.